Associations of Cognitive Function with Serum Magnesium and Phosphate in Hemodialysis Patients: A Cross-Sectional Analysis of the Osaka Dialysis Complication Study (ODCS)
Authors:
- Tetsuo ShojiTSTetsuo Shoji
- Katsuhito MoriKMKatsuhito Mori
- Yu NagakuraYNYu Nagakura
- Daijiro KabataDKDaijiro Kabata
- Kaori KuriuKKKaori Kuriu
- Shinya NakataniSNShinya Nakatani
- Hideki UedonoHUHideki Uedono
- Yuki NagataYNYuki Nagata
- Hisako FujiiHFHisako Fujii
- Yasuo ImanishiYIYasuo Imanishi
- Tomoaki MoriokaTMTomoaki Morioka
- Masanori EmotoMEMasanori Emoto
Open Access
Abstract
Cognitive impairment and dementia are common in patients with chronic kidney disease, including those undergoing hemodialysis. Since magnesium and phosphate play important roles in brain function and aging, alterations in these and other factors related to bone mineral disorder (MBD) may contribute to low cognitive performance in patients on hemodialysis. This cross-sectional study examined the associations between cognitive function and MBD-related factors among 1207 patients on maintenance hemodialysis. Cognitive function was assessed by the Modified Mini-Mental State examination (3MS). The exposure variables of interest were serum magnesium, phosphate, calcium, calcium–phosphate product, intact parathyroid hormone, fetuin-A, T50 calciprotein crystallization test, use of phosphate binders, use of cinacalcet, and use of vitamin D receptor activators. Multivariable-adjusted linear regression models were used to examine the associations between 3MS and each of the exposure variables independent of 13 potential non-mineral confounders. We found that lower 3MS was associated with lower serum magnesium, lower phosphate, lower calcium–phosphate product, and nonuse of phosphate binders. These results suggest that magnesium and phosphate play potentially protective roles against cognitive impairment in this population.Keywords
Funding Information
- Japan Society for the Promotion of Science (22K08360, JKFB 15-43, RS01442, AC-120150630164707-161208, A160602)
- Kidney Foundation, Japan (22K08360, JKFB 15-43, RS01442, AC-120150630164707-161208, A160602)
- Astellas Pharma (22K08360, JKFB 15-43, RS01442, AC-120150630164707-161208, A160602)
- Chugai Pharmaceuticals Co. Ltd. (22K08360, JKFB 15-43, RS01442, AC-120150630164707-161208, A160602)
- Daiichi-Sankyo (22K08360, JKFB 15-43, RS01442, AC-120150630164707-161208, A160602)
This publication has 56 references indexed in Scilit:
- Association between serum magnesium levels and cognitive function in patients undergoing hemodialysisClinical and Experimental Nephrology, 2024
- Association Between Disturbed Serum Phosphorus Levels and QT Interval ProlongationKidney International Reports, 2024
- Association between magnesium intake and cognition in US older adults: National Health and Nutrition Examination Survey (NHANES) 2011 to 2014Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- Association of magnesium intake and vitamin D status with cognitive function in older adults: an analysis of US National Health and Nutrition Examination Survey (NHANES) 2011 to 2014European Journal of Nutrition, 2020
- Can magnesium reduce central neurodegeneration in Alzheimer's disease? Basic evidences and research needsNeurochemistry International, 2019
- Potential therapeutic system for Alzheimer’s disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patientsJournal of Neural Transmission, 2012
- Phosphate and KlothoKidney International, 2011
- Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitusMetabolism, 2010
- Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitusMetabolism, 2008
- Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatmentJournal of the Neurological Sciences, 1995